Corrigendum to “Beneficial immune-regulatory effects of novel strains of Aureobasidium pullulansAFO-202 and N-163 produced beta glucans in Sprague Dawley rats” [Clinical Immunology Communications 1 (2021) 29–34]

Ítems similars

• Corrigendum to “Beneficial immune-modulatory effects of the N-163 strain of Aureobasidium pullulans-produced 1,3-1,6 Beta glucans in Duchenne muscular dystrophy: Results of an open-label, prospective, exploratory case-control clinical study” [IBRO Neurosci. Rep. 15 (2023), pp. 90–99]
  per: Kadalraja Raghavan, et al.
  Publicat: (2023-12-01)
• Corrigendum to “Beneficial immune-regulatory effects of novel strains of Aureobasidium pullulansAFO-202 and N-163 produced beta glucans in Sprague Dawley rats” [Clinical Immunology Communications 1 (2021) 29–34]
  per: Nobunao Ikewaki, et al.
  Publicat: (2024-12-01)
• Randomised trial of Aureobasidium pullulans-produced beta 1,3-1,6-glucans in patients with Duchenne muscular dystrophy: favourable changes in gut microbiota and clinical outcomes indicating their potential in epigenetic manipulation
  per: Naoki Yamamoto, et al.
• Improvement of behavioural pattern and alpha-synuclein levels in autism spectrum disorder after consumption of a beta-glucan food supplement in a randomised, parallel-group pilot clinical study
  per: Tohru Sonoda, et al.
  Publicat: (2022-02-01)
• Resolution of fibrosis in mdx dystrophic mouse after oral consumption of N-163 strain of Aureobasidium pullulans produced β-glucan
  per: Senthilkumar Preethy, et al.
  Publicat: (2023-10-01)